Autologous primary prostate cells or cancer cell lines were inhibited by silencing STAT3 and IL-6 signaling using fludarabine, a STAT3 inhibitor, and tocilizumab, an IL-6 inhibitor. The gene discussed is STAT3; the disease is cancer.